Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Glioblastoma 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Gliosarcoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 30Nivolumab 15Paclitaxel 13Cyclophosphamide 12Carboplatin 12sacituzumab govitecan 8Cisplatin 8Capecitabine 7130-nm albumin-bound paclitaxel 7Gemcitabine 6fludarabine 5durvalumab 5avelumab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Biopsy 5camrelizumab 4Specimen Handling 4Interleukin-2 4Injections 4Immune Checkpoint Inhibitors 4Docetaxel 4toripalimab 3talazoparib 3Leucovorin 3Everolimus 3Clinical Trials, Phase II as Topic 3Bevacizumab 3yeast-CEA vaccine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Triple Negative Breast Neoplasms × pamiparib × Clear all
NCT03333915 2025-02-04

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

BeiGene

Phase 1/2 Completed
128 enrolled 36 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡